Avadel Pharmaceuticals (AVDL) Change in Accured Expenses: 2015-2022
Historic Change in Accured Expenses for Avadel Pharmaceuticals (AVDL) over the last 8 years, with Dec 2022 value amounting to -$4.0 million.
- Avadel Pharmaceuticals' Change in Accured Expenses fell 165.40% to -$4.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was $227,000, marking a year-over-year decrease of 74.64%. This contributed to the annual value of $16.4 million for FY2024, which is 2.77% down from last year.
- Avadel Pharmaceuticals' Change in Accured Expenses amounted to -$4.0 million in Q4 2022, which was down 335.74% from $1.7 million recorded in Q3 2022.
- Avadel Pharmaceuticals' Change in Accured Expenses' 5-year high stood at $3.3 million during Q2 2021, with a 5-year trough of -$6.6 million in Q4 2020.
- For the 3-year period, Avadel Pharmaceuticals' Change in Accured Expenses averaged around -$1.0 million, with its median value being -$640,500 (2021).
- In the last 5 years, Avadel Pharmaceuticals' Change in Accured Expenses plummeted by 341.26% in 2020 and then skyrocketed by 334.88% in 2021.
- Quarterly analysis of 5 years shows Avadel Pharmaceuticals' Change in Accured Expenses stood at $1.0 million in 2018, then spiked by 168.24% to $2.7 million in 2019, then plummeted by 341.26% to -$6.6 million in 2020, then spiked by 76.88% to -$1.5 million in 2021, then slumped by 165.40% to -$4.0 million in 2022.
- Its last three reported values are -$4.0 million in Q4 2022, $1.7 million for Q3 2022, and $245,000 during Q2 2022.